Alliqua secures $13M
LANGHORNE, Pa. - Alliqua has closed a set of deals that brings the company two new products and $13 million in investments, the Philadelphia Business Journal reports. “Alliqua now has significant capital to bring our business plans to fruition,” said CEO David Johnson in the story. In a deal with Celgene, Alliqua obtained the rights to develop and market advanced wound care products Biovance and Extracellular Matrix, and Celgene purchased $6 million in Alliqua stock. Separately, Broadfin Capital and Perceptive Advisors rounded up $7 million in investment capital for Alliqua, according to the story.